Buy Zyceva : Erlotinib 150 mg Tablet 30’S Online

Description

Description: Zyceva is a pharmaceutical product manufactured by Zydus Oncosciences. It contains Erlotinib as its active substance and is primarily used in the treatment of certain types of cancer, particularly non-small cell lung cancer (NSCLC) and pancreatic cancer. Zyceva is available in tablet form, with each tablet containing 150 mg of Erlotinib.

Active Substance: Erlotinib is a tyrosine kinase inhibitor that works by blocking the activity of the epidermal growth factor receptor (EGFR), a protein involved in cell growth and proliferation. By inhibiting EGFR, Erlotinib interferes with the signaling pathways that promote cancer cell growth and survival. Erlotinib is used in the treatment of advanced or metastatic NSCLC with specific EGFR mutations and in combination with gemcitabine for the treatment of metastatic pancreatic cancer.

Manufacturer: Zyceva is manufactured by Zydus Oncosciences, a division of Zydus Cadila Healthcare Ltd., known for its commitment to producing high-quality medications for the treatment of cancer and other serious diseases. Zydus Oncosciences adheres to stringent manufacturing standards to ensure the safety, efficacy, and consistency of its products.

Strength and Formulation: Each pack of Zyceva contains 30 tablets, with each tablet containing 150 mg of Erlotinib as the active ingredient. The tablets are formulated for oral administration, making them convenient for patients to take as directed by their healthcare provider.

Indications: Zyceva (Erlotinib) is indicated for the treatment of the following:

1. Non-small cell lung cancer (NSCLC): Zyceva is used as a first-line treatment for patients with metastatic NSCLC whose tumors have specific EGFR mutations, including exon 19 deletions or exon 21 (L858R) substitution mutations.
2. Pancreatic cancer: Zyceva is used in combination with gemcitabine for the treatment of metastatic pancreatic cancer in patients who have not received previous chemotherapy or whose disease has progressed after gemcitabine-based therapy.

Usage and Dosage: The recommended dosage of Zyceva (Erlotinib) may vary depending on factors such as the patient’s medical condition, treatment response, and tolerability. It is usually taken orally once daily, with or without food, at the same time each day. The tablets should be swallowed whole with water and should not be crushed, chewed, or divided.

Storage Conditions: Zyceva tablets should be stored according to the manufacturer’s instructions, typically in a cool, dry place, away from direct sunlight, and at room temperature. They should be kept out of reach of children and pets to prevent accidental ingestion. Proper storage helps maintain the stability and efficacy of the medication.

Patients should consult their healthcare provider for personalized information regarding the use of Zyceva, including dosage adjustments, potential side effects, and monitoring during treatment. Regular follow-up appointments are essential to evaluate treatment response and manage any adverse reactions.